HopeStage
Back to all studies
CompletedNCT06138691

KET-RO and RO DBT for treatment-resistant depression

About this titleRead the official source — NCT06138691
Interventional studyAges 18–65United States
The study in practice

Understand this study

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
St LouisSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: October 4, 2023
Recruitment status
Completed
Enrollment listed in the registry
16
Sponsor
Washington University School of Medicine
Sponsor type
University
Study type
Drug
Intervention type
Combination product
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT06138691
Official title
Show the full official title

Medication-assisted Psychotherapy: Using Ketamine-enhanced Radically Open Dialectical Behavior Therapy (RO DBT) to Target Neural and Behavioral Mechanisms of Action in Adults With Moderate to Severe Depression

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

St Louis

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Washington University School of Medicine, a university.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies